DailyIQ
Last updatedjust now

WST·West Pharmaceutical Services, Inc.

$376.10
+4.28 (+1.15%)
High
$379.21
Open
$372.21
Market Cap
27.19B
52W High
$394.37
Low
$372.21
P. Close
$376.10
P/E
48.13
52W Low
$223.83
Fwd P/E
37.81
DailyIQ Est.
$426.76
Inst. Ownership
45.8%
Short Interest
2.87%
Days to Cover
3.1
Div. Yield
0.24%
Next Ex-Div
~Oct 28
Div. Growth
33+ yrs
Technical Score (1D)
80
BULLISH
News Sentiment
45
MIXED
With a Technical Score of 80, West Pharmaceutical Services, Inc. (WST) sits in the upper tier of the momentum ranking on the 1D timeframe. The bullish bias and BUY signal follow from that rank, and trend strength reads as strong. Sentiment at 45 is diverging from the chart. Because the score is relative, it can stay high while the broader market falls, as long as WST holds up better than its peers. $356.95 is the near-term risk reference and $397.85 is the next upside marker if buyers keep pressing. A top momentum rank reflects the prior year of trading, so it changes gradually. Day to day, price levels give the earlier read: a decisive close below $356.95 would say more about near-term risk than the rank itself, while holding above it keeps $386.69 in play.
LOW TARGET
$340 -9.6%
1 analysts
MEAN TARGET
$413 +9.8%
13 analysts
HIGH TARGET
$459 +22.0%
11 analysts
PRICE RANGE
$340.00 - $459.00
SB / B / H / S / SS
7/14/2/1/1
DAILYIQ EST.
$426.76 (+13.5%)
Sector
Healthcare
Industry
Medical Instruments & Supplies
Exchange
NYQ
Country
United States
Symbol
WST
Description
West Pharmaceutical Services, Inc. is a global provider of containment and delivery systems for injectable drugs and healthcare products, serving the pharmaceutical industry across multiple continents. The company operates through two primary segments: Proprietary Products and Contract-Manufactured Products. Its Proprietary Products segment focuses on developing and supplying critical components like stoppers, seals, syringes, and advanced drug delivery systems, including innovative solutions like Crystal Zenith. Simultaneously, the Contract-Manufactured Products segment designs and assembles devices for surgical, diagnostic, and drug delivery applications. West Pharmaceutical Services, Inc. distributes its products through a combination of direct sales, distribution networks, and contract agents, solidifying its position as a key partner for pharmaceutical and medical device companies.
Bought (1Y)
0 shares
$0
Sold (1Y)
18,987.446 shares
$6.6M
HAUGEN JANET BRUTSCHEA-
Award/Grant44 shares2026-09-30
Favorite Annette FSr. VP & Chief HR Officer
Option Exercise2,524 shares2026-09-15
Favorite Annette FSr. VP & Chief HR Officer
Sell2,524 shares2026-09-15
Favorite Annette FSr. VP & Chief HR Officer
Option Exercise2,524 shares2026-09-15
Favorite Annette FSr. VP & Chief HR Officer
Option Exercise2,500 shares2026-09-14
79/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
35.9%
Net Margin
16.1%
Revenue CAGR
6.5%
Current Ratio
3.02x
Debt / Equity
0.06x
Return on Equity
15.5%
Earnings Summary
West Pharmaceutical Services, Inc. is a global provider of containment and delivery systems for injectable drugs and healthcare products, operating through Proprietary and Contract‑Manufactured Products segments that supply critical components such as stoppers, seals, syringes, and advanced drug delivery systems, including Crystal Zenith, to pharmaceutical and medical device companies worldwide. The company sits within the healthcare sector’s medical instruments and supplies industry, serving a highly regulated and innovation‑driven market. In the most recent quarters, West delivered EPS of $1.82 in Q4 2024, beating the $1.73 estimate, and $1.45 in Q1 2025, surpassing the $1.26 estimate, while revenue rose to $748.8 million and $698 million respectively; Q2 2025 EPS of $1.84 exceeded the $1.54 estimate and revenue climbed to $766.5 million, and Q3 2025 EPS of $1.96 beat the $1.71 estimate with revenue at $804.6 million. The company’s Q4 2025 EPS of $2.04 outpaced the $1.67 estimate and revenue of $805 million surpassed the $773.5 million estimate, continuing a pattern of earnings beats in four consecutive quarters and revenue growth in each period. Historically, West has shown a steady YoY revenue expansion, with each quarter’s earnings exceeding analyst expectations, indicating a consistent ability to generate above‑average profitability despite modest revenue fluctuations. Recent news highlights from October 7 underscore analyst confidence, with Evercore ISI and Barclays both raising price targets to $440 and maintaining buy ratings, citing double‑digit earnings growth in the GLP‑1 segment and a multiyear regulatory conversion opportunity under Annex 1 that has already captured $1 billion of a $6 billion potential; these developments reinforce the narrative that high‑value platform upgrades and regulatory conversions are key revenue drivers.

EPS

EstBeatMiss
$1.12$1.42$1.73$2.03$2.34Q1'25Q2'25Q3'25Q4'25Q1'26Q3'26
QtrEstActual+/−
Q3'26$2.20 - -
Q1'26$2.05$2.13+3.8%
Q4'25$1.67$2.04+22.1%
Q3'25$1.71$1.96+14.6%
Q2'25$1.54$1.84+19.7%
Q1'25$1.26$1.45+15.3%

Revenue

EstBeatMiss
$676M$724M$771M$819M$867MQ1'25Q2'25Q3'25Q4'25Q1'26Q3'26
QtrEstActual+/−
Q3'26$827M - -
Q1'26$835M$845M+1.2%
Q4'25$773M$805M+4.1%
Q3'25 - $805M -
Q2'25 - $767M -
Q1'25 - $698M -

Market Data

WST Stock Snapshot

BULLISH80/100
$376.10+$4.28 (1.2%)
Market cap
27.19B
P/E ratio
48.1
Day range
$372.21 – $379.21
News sentiment
45/100 · Neutral
Analyst target
$412.88 (+9.8%)
Consensus
Buy · 25 analysts
52-week range+68.0% off low · -4.6% from high
$223.83$394.37
Price $376.10 DailyIQ Est. $426.76

WST is trading with the trend behind it, which is what pushes the technical read bullish. In Healthcare, names this size usually take direction from sector flows before company-level news.

Reverse DCF

What growth is priced into WST?

RICH

At today's price, West Pharmaceutical Services, Inc. needs to grow free cash flow about 33.8% a year for the next 10 years to justify its valuation at a 8.81% cost of capital. Over its actual history it has compounded free cash flow at 18.8% a year, so the market is asking for 15.0 percentage points above its own delivered rate. On that basis WST looks priced above what its own growth record supports.

Implied FCF growth
33.8%
Historical FCF CAGR
18.8%
Growth gap
+15.0 pts
Verdict
RICH
Discount rate (WACC)
8.81%
Beta
0.72

Behaviour On Record

What WST's own history says about today's numbers

Realized volatility (21d)
23.0% 44th pct
Below its peak
-21.1%
vs 200-day average
+21.8%
Up days (1y)
53%

West Pharmaceutical Services, Inc. is currently running 23.0% annualised volatility over the last 21 sessions. Measured against WST's own 13 years of daily returns rather than a market-wide average, that is the 44th percentile — close to its own typical level, against a typical reading of 24.4%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

WST is trading -21.1% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -22.9%, and the deepest was -53.0% in 2022. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +21.8% from its 200-day moving average. Against every other day in its history, that gap ranks at the 85th percentile — a wider gap than this stock usually carries. Over the past year WST closed higher on 53% of sessions, and it is currently 3 sessions into a rising streak.

On October specifically: over 13 years of records, WST finished the month higher 9 of 13 times, with a median return of +2.7% and an average of +1.3%. Its strongest month historically has been June at +4.6% on average, its weakest February at -2.1%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: WST has opened more than 2% away from the prior close in 91 of 3,267 sessions (2.8% of the time), with the largest gaps running +9.1% and -15.7%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against WST's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of WST's sector?

West Pharmaceutical Services, Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
91

Options Market

What is the options market pricing for WST?

CallsPuts

For West Pharmaceutical Services, Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.18), with at-the-money implied volatility around 32.7%. The options market is pricing roughly a ±3.1% move by that expiry — a range of about $364.72–$387.70.

Put/call ratio (2026-10-16)
0.18
ATM implied volatility
32.7%
Total open interest
1,022
Expected move by 2026-10-16
±3.1% ($364.72–$387.70)

Analyst Rating Changes

Are analysts turning bullish or bearish on WST?

TD Cowen most recently reiterated its rating on West Pharmaceutical Services, Inc. to Buy on Oct 13, 2026 with a price target of $420 (from $410). Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.

Latest action
TD Cowen — Buy
90-day upgrades
1
90-day downgrades
0
Net rating momentum
+1
DateFirmActionRatingPrice target
Oct 13, 2026TD CowenMaintainedBuy$410 → $420
Oct 7, 2026BarclaysMaintainedOverweight$400 → $440
Sep 22, 2026Morgan StanleyUpgradeEqual-Weight → Overweight$365 → $400
Sep 9, 2026UBSMaintainedBuy$340 → $415
Aug 3, 2026CitigroupMaintainedBuy$400 → $412
Jul 27, 2026Evercore ISI GroupMaintainedOutperform$410 → $425
Jul 13, 2026BNP ParibasInitiatedOutperform$447
Jul 9, 2026Morgan StanleyMaintainedEqual-Weight$325 → $365
Jul 6, 2026Evercore ISI GroupMaintainedOutperform$390 → $410
Jul 2, 2026KeybancMaintainedOverweight$350 → $390
Jun 9, 2026BarclaysUpgradeEqual-Weight → Overweight$310 → $400
Jun 2, 2026Stephens & Co.ReiteratedOverweight$360

Peers & ETF holders

WST peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

45/100
Strong NegativeNeutralStrong Positive
MIXED

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
West Pharmaceutical Services, Inc. (NYSE: WST) announced on October 8, 2026 that it would release its third‑quarter 2026 financial results before the market opened on October 29, 2026, followed by a conference call at 8:00 a.m. Eastern Time to discuss the results and business expectations. The company provided details on how investors could access the webcast and register for the call, and noted that a replay would be available for approximately 90 days.
What did this article say?
The analyst concluded that West Pharmaceutical Services must accelerate earnings growth to justify its premium valuation. The report highlighted that current financial performance is insufficient to support the stock’s high price‑to‑earnings ratio. It emphasized the need for stronger cash flow and earnings momentum to avoid a downgrade or sell recommendation. The analysis suggested that without measurable improvement, the company’s valuation may be overextended.
What did this article say?
West Pharmaceutical Services’ share price has surged 37.2% over the past year, prompting analysts to question whether the company’s cash flows can sustain the current valuation. The firm’s role in supplying critical drug delivery components suggests resilient demand, yet its 45.7x P/E ratio and projected cash flow shortfall raise doubts about intrinsic value.
What did this article say?
Evercore ISI increased its price target for West Pharmaceutical Services (WST) from $410 to $440, reflecting a more optimistic view of the company’s prospects. The rating remains a buy, and the new target aligns with the average analyst estimate of $409.73. The upgrade suggests confidence in WST’s growth trajectory and earnings potential.
What did this article say?
Barclays analyst Luke Sergott upgraded West Pharmaceutical Services (WST) to an Overweight rating and increased its price target from $400 to $440. The upgrade reflects confidence in WST’s earnings outlook and growth prospects. The move signals a positive sentiment for the company’s future performance. No immediate catalysts were cited beyond the rating change. The adjustment is expected to influence investor perception and trading activity.
What did this article say?
West Pharmaceutical Services (WST) was reaffirmed as a buy on October 7, with analysts citing robust double‑digit earnings growth from GLP‑1 products and a multiyear regulatory conversion opportunity under Annex 1. The company’s high‑value platform upgrades (HVP) and the conversion of a $1 billion portion of a $6 billion Annex 1 opportunity were highlighted as key catalysts. Analysts noted that maintaining the premium valuation will require continued execution on these drivers, but the current outlook remains bullish. The report emphasized that the valuation remains demanding, yet the growth prospects justify the support.
What did this article say?
Barclays increased its price target for West Pharmaceutical Services (WST) to $440 from $400, maintaining an overweight rating. The upgrade reflects confidence in WST’s product portfolio and growth prospects. The brokerage highlighted the company’s strong earnings trajectory and expanding market share in the pharmaceutical services sector. This adjustment signals a positive market view and may influence investor sentiment toward WST.
What did this article say?
West Pharmaceutical Services (WST) is expected to report fiscal Q3 2026 earnings with a projected diluted EPS of $2.18, up 11.2% from the prior quarter. The company has consistently beat Wall Street estimates in its last four reports, reinforcing its earnings momentum. For the full year, analysts anticipate EPS of $8.93, a 22.5% increase over fiscal 2025, indicating sustained profitability growth.
What did this article say?
West Pharmaceutical Services announced its participation in CPHI Worldwide in Milan, Italy, where it planned to showcase its leadership in injectable drug packaging and delivery solutions. The company highlighted its SelfDose® patient-controlled injector and the West Synchrony® S1 prefillable syringe system as examples of patient‑centered design. The event was intended to reinforce West’s position as a key partner for pharmaceutical manufacturers in addressing complex packaging challenges. No immediate financial or strategic shifts were disclosed, and the announcement was framed as a routine industry engagement.
What did this article say?
West Pharmaceutical Services reported its Q2 earnings, positioning itself among the top performers in the drug development inputs and services sector. The company’s business model relies on long‑term contracts with biopharma firms, providing support for drug discovery, preclinical testing, and manufacturing. Demand for its services is expected to grow with increasing investment in biologics, cell and gene therapies, and other advanced therapeutics. While capital intensity and customer concentration pose risks, the company’s stable revenue base and strategic partnerships mitigate short‑term volatility. The earnings release reinforced investor confidence in WST’s market standing and future growth prospects.

Technical Analysis

Real-time indicators across multiple timeframes

80
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $11.10B combined position · 13 adding, 12 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▼ Sell9,539,17313.05%$2.62B2026-01-29
BlackRock, Inc.▼ Sell6,651,7849.10%$2.39B2026-08-07
FMR LLC (Fidelity)▲ Buy3,574,8164.89%$1.28B2026-08-13
Artisan Partners Limited Partnership▼ Sell2,411,7923.30%$865.83M2026-08-13
Geode Capital Management, LLC▼ Sell1,903,2792.60%$680.55M2026-08-12
Morgan Stanley▲ Buy1,582,5462.16%$568.14M2026-08-13
JPMorgan Chase & Co▲ Buy1,164,5271.59%$413.03M2026-08-12
Invesco Ltd.▼ Sell1,009,8521.38%$362.54M2026-08-14
Norges Bank▼ Sell862,9151.18%$309.79M2026-08-12
Goldman Sachs Group Inc▲ Buy814,7721.11%$292.50M2026-08-14
Northern Trust Corp▼ Sell709,4210.97%$254.68M2026-08-13
Capital Research Global Investors▲ Buy609,2210.83%$218.71M2026-08-12
William Blair Investment Management, LLC▲ Buy417,3090.57%$149.81M2026-08-12
Citadel Advisors LLC▲ Buy352,7690.48%$126.64M2026-09-02
Bank of America Corp▼ Sell350,4820.48%$125.82M2026-08-14
Point72 Asset Management, L.P.▲ Buy283,3960.39%$101.74M2026-08-14
Citigroup Inc▲ Buy190,7780.26%$68.49M2026-08-03
Wellington Management Group LLP▼ Sell175,0520.24%$62.84M2026-08-14
Prudential Financial Inc▲ Buy143,3280.20%$51.45M2026-08-12
Wells Fargo & Company▲ Buy114,1070.16%$40.96M2026-08-14
Marshall Wace, LLP▲ Buy83,5780.11%$30.00M2026-08-13
Adage Capital Partners GP, L.L.C.▼ Sell59,0070.08%$21.18M2026-08-14
AQR Capital Management LLC▼ Sell57,6090.08%$20.33M2026-08-14
AllianceBernstein L.P.▼ Sell76,3560.10%$19.14M2026-08-14
Balyasny Asset Management L.P.▲ Buy45,7660.06%$16.43M2026-08-14
Q2 2026 flow:3.43M sh bought ($1.23B)964.4K sh sold ($343.76M)net +2.47M sh (+$888.04M)
Congressional Trading Activity
8 disclosed trades · ~$64.0K est. traded value · 3 buys, 5 sells
MemberChamberStateTypeAmountTradedFiled
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-07-222025-08-13
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-06-172025-08-13
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-04-082025-05-08
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-02-252025-03-27
Jared MoskowitzHouseFL23▼ Sell$1K - $15K2025-02-132025-03-06
Tommy TubervilleSenateAL▼ Sell$1K - $15K2022-03-302022-04-08
Tommy TubervilleSenateAL▲ Buy$1K - $15K2021-03-292021-07-23
Thom TillisSenateNC▼ Sell$1K - $15K2015-02-132015-02-26